

MCTW

2023

XVIII. Myeloma VI. Cell Therapy Workshop

Organizing committee

Prof. Roman Hájek, MD, PhD
Renata Šnaurová
Jana Kotulová, PhD
Nikola Garbová
Daniela Gachová



SCIENTIFIC SESSIONS

SESSION I – MULTIPLE MYELOMA: HOT TOPICS

SESSION II – CHALLENGES IN BIOINFORMATICS

SESSION III – NEW HORIZONS OF CELL
THERAPY TREATMENT IN RARE MONOCLONAL
GAMMOPATHIES

SESSION IV – IMMUNOTHERAPIES IN
HEMATOLOGIC MALIGNANCIES

PANEL DISCUSSION

How to Improve Prediction of Patient
Response to Immunotherapy (CAR-T and/or
bispecific MoAbs)?

SESSION V – ACADEMIC APPROACH
TO CAR-T THERAPY

ABOUT THE WORKSHOP

The two-day international meeting focused on hematological malignancies, particularly multiple myeloma immunotherapy, immunomonitoring, and cell therapies. It fosters multidisciplinary collaborations, bringing together researchers, clinicians, and bioinformaticians to discuss and advance current knowledge.

The event is held under the auspices of the Blood Cancer Research Group (University of Ostrava, Faculty Hospital Ostrava) and the Czech Myeloma Group.

10:00 Opening remarks (Prof. Roman Hájek, MD, PhD)

SESSION I – MULTIPLE MYELOMA: HOT TOPICS

Chair: Assoc. Prof. Tomáš Jelínek, MD

10:15 Circulating Tumor Plasma Cells

Assoc. Prof. Tomáš Jelínek, MD – Blood Cancer Research Group, Ostrava, Czech Republic

10:40 CAR-T Cell Therapy for All Patients?

Nico Gagelmann, MD – University Medical Center Hamburg-Eppendorf, Hamburg, Germany

11:00 Hot Topics in Multiple Myeloma Risk Stratification

Mattia D'Agostino, MD – University of Turin, Turin, Italy

11:20 – 11:40 COFFEE BREAK + POSTER SESSION FOR EVERYONE

SESSION II – CHALLENGES IN BIOINFORMATICS

Chair: David Žihala, PhD

11:40 Unraveling Molecular Resistance and Kinetics in Multiple Myeloma: Insights from CTCs and MRD

Camila Guerrero, MSc – Clínica Universidad de Navarra, Pamplona, Spain

12:00 The Spatio-Temporal Evolution of Myeloma

Leo Rasche, MD (online) – University Hospital of Würzburg, Würzburg, Germany

12:20 Longitudinal Multi-Omics Study Reveals Molecular Drivers and Tumor Microenvironment in Extramedullary Multiple Myeloma

Tereza Ševčíková, PhD – Blood Cancer Research Group, Ostrava, Czech Republic

12:40 Individualized Prediction Model in Myeloma

Francesco Maura, MD (online) – University of Miami, Miami, FL, USA

13:00 – 14:00 LUNCH BREAK + POSTER SESSION FOR EVERYONE

SESSION III – NEW HORIZONS OF CELL THERAPY TREATMENT IN RARE MONOCLONAL GAMMOPATHIES

Chair: Zuzana Chyra, PhD / Tereza Popková, MD

14:00 Safety and Efficacy of Locally Produced Novel BCMA-CART for the Treatment of Relapsed and Refractory MM and AL Amyloidosis

Moshe Gatt, MD (online) – The Hebrew University of Jerusalem, Jerusalem, Israel

14:20 CAR-T Therapy for Multiple Myeloma: Mission Accomplished?

Prof. Michael Hudeček, MD (online) – University Hospital of Würzburg, Würzburg, Germany

14:45 Defining the Pro-Survival Signalling of the Bone Marrow Microenvironment of Multiple Myeloma

Graeme Sullivan, PhD – Trinity College, Dublin, Ireland

15:05 Cellular Therapies in Waldenström Macroglobulinemia and AL Amyloidosis

Shayna Sarosiek, MD (online) – Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA

15:25 – 15:30 Closing remarks of the 1st day

15:30 – 15:45 COFFEE BREAK

15:45 – 15:55 Poster evaluation by committee

18:30 Social dinner at Hola Bar & Tapas

SESSION IV – IMMUNOTHERAPIES IN HEMATOLOGIC MALIGNANCIES

Chair: Piotr Celichowski, PhD

10:00 Development of Allogeneic Cell Therapy in Ostrava

Piotr Celichowski, PhD – *Blood Cancer Research Group, Ostrava, Czech Republic*

10:25 The Role of Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma

Włodzimierz Mendrek, MD, PhD – *Maria Skłodowska-Curie Memorial Cancer Centre and Institute of Oncology, Gliwice, Poland*

10:50 Allogeneic CAR-T for Myeloma – Lessons from Recent Allo CAR-T Trials

Reuben Benjamin, MBBS, FRCPath, PhD – *Kings College London, London, UK*

11:10 Efficacy of CD19-Directed CAR-T Cells Against CLL and the Possibilities for Its Further Improvements

Mgr. Michal Šmída, Dr. rer. nat. – *Central European Institute of Technology (CEITEC), Masaryk University, Brno, Czech Republic*

11:30 – 11:45 COFFEE BREAK**11:45 – 12:45 PANEL DISCUSSION**

How to Improve Prediction of Patient Response to Immunotherapy (CAR-T and/or bispecific MoAbs)?

12:45 – 13:45 LUNCH BREAK

13:45 – 14:05 Poster Winners Awards

SESSION V – ACADEMIC APPROACH TO CAR-T THERAPY

Chair: Prof. Roman Hájek, MD, PhD

14:05 Academic Approach to CAR-T Therapy - UHKT/IHBT Prague Czech Republic

Petr Lesný, MD, PhD – Institute of Haematology and Blood Transfusion, Prague, Czech Republic

14:25 Academic Approach to CAR-T Therapy - University Medical Centre Ljubljana, Slovenia

Prof. Matjaž Sever, MD, PhD (online) – University Medical Centre Ljubljana, Slovenia

14:45 Quality Control Steps of Non-Viral CAR-T

Ivana Ťapuchová, MSc & Assoc. Prof. Irena Koutná, PhD – St. Anne's University Hospital, Brno, Czech Republic

15:05 Current Development of Adoptive CAR-T Cell Therapy in Poland

Włodzimierz Mendrek, MD, PhD – Maria Skłodowska-Curie Memorial Cancer Centre and Institute of Oncology, Gliwice, Poland

15:25 – 15:30 Closing remarks of the MCTW 2023

XIX. Myeloma & VII. Cell Therapy Workshop

Organized by Blood Cancer Research Group & Czech Myeloma Group

OCTOBER 10–11, 2024

Ostrava | Czech Republic

SAVE THE DATE!



We would like to thank the following companies for their continued support.

AMGEN

BIOHEM

GSK

produkty pre medicínu

sanofi

 **Bristol Myers Squibb™**

janssen

PHARMACEUTICAL COMPANIES
OF *Johnson & Johnson*



Follow BCRG for the updates!

